Replies to post #134686 on Biotech Values

[DewDiligence]

Presidio provides update on its NS5A inhibitor, PPI-668:

http://finance.yahoo.com/news/presidio-pharmaceuticals-announces-phase-1a-040000825.html

PPI-668 is the successor to PPI-461, a drug that Presidio acquired from XTLB at a firesale price about four years ago (#msg-27791536).

p.s. If XTLB had waited until now to sell a preclinical NS5A inhibitor, they probably could have walked away with real money :- )